Jonas Skov has experience with a wide range of quality assurance and regulatory tasks. He has been responsible for release of medicine for EU, US and AUS markets, and through this in charge of complaints handling, deviation handling, process optimization, standard operation procedures and internal audits.

As Head of Regulatory Affairs Jonas will work with CannGros' growing product portfolio. He will be responsible for the registration and approval of self-produced and imported products, thus helping to ensure that the DanCann Pharma Group always live up to both Danish and as international regulatory requirements. He will be responsible for regulatory processes and tasks - both preparation, implementation, follow-up and optimization and must ensure, that CannGros is introduced to new regulatory requirements

Jonas is looking forward to his participation in the development of CannGros as an important contributor to the Danish and European markets.   

Jonas Skov comments:

- CannGros and DanCann Pharma are young and ambitious companies with very dedicated teams of employees. When I got the opportunity, it was an easy decision for me to join and be part of the Group. I have gained my experience by working with a wide range of RA/QA tasks and therefore have an extensive knowledge of what my role as Head of Regulatory Affairs contains. I thrive in an environment with a varied workday, which also reflects in the many different tasks I undertake.

- I particularly enjoy working on interdisciplinary project assignments where I get a chance to think across boundaries. I am a dedicated entrepreneur and very proud to be a part of the DanCann Pharma Group moving fast forward with colleagues who share my strong passion for improving quality of life for patients with challenges.

Louise Conradsen, CEO at CannGros, elaborates: 

- As a result of our EU-GMP approval and increasing commercial activities, we must strengthen our organization in the regulatory field. We have been searching for the right candidate with the relevant profile for quite some time and strongly believe to have found this in Jonas. Jonas' experience from the industry will be an essential asset for CannGros and the DanCann Pharma Group and will help us take a huge step towards fulfilling our ambitions. We are in an industry where we constantly meet regulatory challenges and to have a fully dedicated Head of Regulatory Affairs will be a significant addition to our team. I look very much forward to working closely with Jonas.

Jonas Skov starts at CannGros on the 2[nd] of January 2023.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas. DanCann Pharma is EU-GMP-approved by the Danish Medicines Agency under the Danish Pilot Programme for medical cannabis, and have, among other things, license for manufacturing, export, import and distribution.

The Company has an ambition to deliver a qualified and standardized product - prepared according to standards that apply in the manufacture of conventional medicine. The DanCann Pharma group also owns the subsidiary CannGros ApS, which is the market leader in Denmark with the import and distribution of the products Bedrocan®, Bedica® and Bediol® to all the Danish pharmacies.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm and sidelisted on OTCQB Venture Market in USA (DCPXF).

For more information, visit: www.dancann.com  

For further information, please contact:

Jeppe Krog Rasmussen, CEO

E-mail: jkr@dancann.com 

Website: www.dancann.com  

Disclaimer

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.